Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
CFD
Stock CFD Derivatives
US Stocks
Access real US stocks and ETFs
HK Stocks
Trade quality Hong Kong-listed stocks
Korean Stocks
SK Hynix
Real Korean stocks and top assets
Stock Futures
High leverage, 24/7 trading
Tokenized Stocks
Backed by real stock assets
IPO Access
Unlock full access to global stock IPOs
GUSD
3.8%
Mint GUSD for Treasury RWA yields
Stocks Activities
Trade Popular Stocks and Unlock Generous Airdrops
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
IPO Access
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
US Stock Insider Trading | Xenon Pharmaceuticals disclosed two insider trading transactions on March 13
On March 13, 2026, Xenon Pharmaceuticals (XENE) disclosed two insider trading transactions. Director MORTIMER IAN sold 7,308 shares.
【Recent Insider Trading】
| Disclosure Date | Position | Name | Transaction Date | Buy/Sell | Quantity | Price per Share/USD | Total Amount/USD | | --- | --- | --- | --- | --- | --- | --- | --- | | March 13, 2026 | Director | MORTIMER IAN | March 13, 2026 | Sell | 7,308 | 55.23 | $403.6k | | March 13, 2026 | Executive | KENNEY CHRISTOPHER JOHN | March 13, 2026 | Sell | 1,410 | 55.23 | $77.9k | | March 11, 2026 | Director | MORTIMER IAN | March 9, 2026 | Sell | 21.8k | 58.81 | $1.2815M | | March 11, 2026 | Director | MORTIMER IAN | March 9, 2026 | Sell | 12.5k | 59.50 | $742.5k | | March 11, 2026 | Director | MORTIMER IAN | March 9, 2026 | Buy | 75k | 8.40 | $630.0k | | March 11, 2026 | Director | MORTIMER IAN | March 9, 2026 | Buy | 65k | 9.44 | $613.6k | | March 11, 2026 | Director | MORTIMER IAN | March 9, 2026 | Buy | 105k | 4.75 | $498.8k | | March 11, 2026 | Director | MORTIMER IAN | March 9, 2026 | Buy | 25k | 3.10 | $77.5k | | March 11, 2026 | Director | MORTIMER IAN | March 9, 2026 | Sell | 43.3k | 59.26 | $2.5688M | | March 11, 2026 | Director | MORTIMER IAN | March 9, 2026 | Sell | 31.7k | 59.88 | $1.8978M |
【Company Profile】
Xenon Pharmaceuticals Inc. was incorporated in the Province of British Columbia on November 5, 1996 under its predecessor’s name (Xenon Bioresearch Inc.), pursuant to the Business Corporations Act (British Columbia). The company is a clinical-stage biopharmaceutical company focused on discovering and developing pipeline therapies for orphan indications. The company plans to commercialize itself for larger markets and intends to establish partnerships with global pharmaceutical companies. To develop precision therapies, the company has built a core enabling discovery platform by researching rare human diseases with extreme traits, including diseases caused by ion channel mutations—also known as ion channel gene mutation diseases. The company has an integrated platform that includes internal capabilities such as human genetics, small-molecule drug discovery, and preclinical and clinical development.